{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-003047","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.911969+00:00","generated_at":"2026-06-19T18:38:37.127218+00:00","sec_items":["1.02","5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Isoray terminates Chief R&D Officer William Cavanagh III, expects separation agreement","bullets":["William Cavanagh III terminated as Chief R&D Officer effective Feb 7, 2023; termination triggers his Employment Agreement change-of-control provisions.","Expected separation agreement: accrued wages at $341K annual salary, unreimbursed expenses (request within 5 days), plus one year health insurance premiums.","Separation agreement will include a release of all claims by Cavanagh against the company; no assurance it will be finalized.","Cavanagh remains subject to non-solicitation, non-disparagement, and confidentiality obligations post-termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-003047","json":"https://secwatch.observer/filing/0001437749-23-003047.json","markdown":"https://secwatch.observer/filing/0001437749-23-003047.md","text":"https://secwatch.observer/filing/0001437749-23-003047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774923003047/0001437749-23-003047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774923003047/isr20230210_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T18:38:37.127218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eaafbbf996","claim":"William Cavanagh III was terminated as Chief Research and Development Officer at Perspective Therapeutics, Inc..","evidence_excerpt":"William Cavanagh III was terminated from his position of Chief Research and Development Officer of the Company on February 7, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923003047/0001437749-23-003047-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Research and Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}